|
|
S. Eddahibi, N. Hanoun, L. Lanfumey, K.P. Lesch, B. Raffestin, M. Hamon, S. Adnot
J Clin Invest. 2000;
105(11):1555
doi:10.1172/JCI8678
Abstract |
Full text
| PDF

H
ypoxia is a well-recognized stimulus for pulmonary blood vessel remodeling and pulmonary hypertension development. One mechanism that may account for these effects is the direct action of hypoxia on the expression of specific genes involved in vascular smooth muscle cell (SMC) proliferation. Previous studies demonstrated that the serotonin (5-hydroxytryptamine; 5-HT) transporter (5-HTT) mediates the mitogenic activity of 5-HT in pulmonary vascular SMCs and is overexpressed during hypoxia. Thus, 5-HT-related mitogenic activity is increased during hypoxia. Here, we report that mice deficient for 5-HTT (5-HTT–/–) developed less hypoxic pulmonary hypertension and vascular remodeling than paired 5-HTT+/+ controls. When maintained under normoxia, 5-HTT–/–-mutant mice had normal hemodynamic parameters, low blood 5-HT levels, deficient platelet 5-HT uptake, and unchanged blood levels of 5-hydroxyindoleacetic acid, a metabolite of 5-HT. After exposure to 10% O2 for 2 or 5 weeks, the number and medial wall thickness of muscular pulmonary vessels were reduced in hypoxic 5-HTT–/– mice as compared with wild-type paired controls. Concomitantly, right ventricular systolic pressure was lower and right ventricle hypertrophy less marked in the mutant mice. This occurred despite potentiation of acute hypoxic pulmonary vasoconstriction in the 5-HTT–/– mice. These data further support a key role of 5-HTT in hypoxia-induced pulmonary vascular SMC proliferation and pulmonary hypertension.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(18)
| Title and authors |
Publication |
Year |
Hypertension artérielle pulmonaire disproportionnée : caractéristiques et pronostic d’une cohorte de patients niçois référés au laboratoire d’échocardiographie
T. Hugues, F. Lemoigne, F. Macone, P. Cerboni, P. Gibelin
|
Ann Cardiol Angeiol
|
2012 |
Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor
Dan-Dan Han, Yun Wang, Xin-Hua Zhang, Jin-Rong Liu, Huai-Liang Wang
|
Can. J. Physiol. Pharmacol.
|
2012 |
Anorexigènes et maladies cardiovasculaires : les liaisons dangereuses
P. Yerly, J. -L. Vachiéry
|
Réanimation
|
2011 |
Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension
Hala El Chami, Paul M. Hassoun
|
Comprehensive Physiology
|
2011 |
Amelioration of hypoxia-induced striatal 5-HT2A receptor, 5-HT transporter and HIF1 alterations by glucose, oxygen and epinephrine in neonatal rats
T.R. Anju, C.S. Paulose
|
Neuroscience Letters
|
2011 |
Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.
Laura E Fredenburgh, Jun Ma, Mark A Perrella
|
Trends in Cardiovascular Medicine
|
2009 |
Apoptosis and Effects of Intracavernous Bone Marrow Cell Injection in a Rat Model of Postprostatectomy Erectile Dysfunction
Papa Ahmed Fall, Mohamed Izikki, Li Tu, Salem Swieb, Francois Giuliano, Jacques Bernabe, Rachid Souktani, Claude Abbou, Serge Adnot, Saadia Eddahibi, René Yiou
|
European Urology
|
2009 |
Role of the serotonin transporter in pulmonary arterial hypertension
Yvonne Dempsie, Margaret R MacLean
|
Expert Rev. Clin. Pharmacol.
|
2008 |
Endothelial cell dysfunction and cross talk between endothelium and smooth muscle cells in pulmonary arterial hypertension
Marc Humbert, David Montani, Frédéric Perros, Peter Dorfmüller, Serge Adnot, Saadia Eddahibi
|
Vascular Pharmacology
|
2008 |
Synergistic heterozygosity for TGFβ1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension
John A Phillips, Justin S Poling, Charles A Phillips, Krista C Stanton, Eric D Austin, Joy D Cogan, Lisa Wheeler, Chang Yu, John H Newman, Harry C Dietz
|
Genetics in Medicine
|
2008 |
|